Global Anemia Drugs Market Overview

Anemia is characterized by weakness, shortness of breath and a general tiredness due to a decrease in the total amount of red blood cells (RBCs) or haemoglobin in the blood. The lowered haemoglobin results in a lowered ability of the blood to carry oxygen. There are three main types of anaemia, i.e. due to blood loss, due to decreased or faulty red blood cell production and due to increased red blood cell breakdown. Anaemia affects a quarter of people of the world and of the different types of anaemia iron deficiency anaemia comprises of the largest number of people affected, about 1 billion and resulting in approximately 215,000 deaths each year. Anaemia is also more common in females than males. It also has a greater propensity to affect children, pregnant and lactating women and the elderly. Factors such as growing geriatric population, increasing awareness, rising focus on women health and, rising prevalence of cancer, poor nutritional habits, rise in lactating and pregnant women in developing regions, intestinal infections etc. are the major drivers for the market growth during the forecast period. However, poor absorption of intravenous iron drugs and the side effects associated with the treatment AND aplastic anemia treatment cost are the restraining factors for the growth of the market during the forecast period.

The global Anemia Drugs Market Revenue is growing with the sound pace. According to a recent study report published by the Market Research Future, the global anemia drugs market is booming and is expected to gain prominence over the forecast period growing rapidly. The market is forecasted to demonstrate a spectacular growth by 2022, surpassing its previous growth records in terms of value with a sound CAGR during the anticipated period (2017 2022).

Global Anemia Drugs Market   - Competitive Analysis

Amgen Inc., GlaxoSmithKline plc, Bluebird bio, Biocon, GlycoMimetics Inc., Regen biopharma Inc., Bayer AG, Acceleron Pharma, Eli Lilly and company are some of the prominent players at the forefront of competition in the global anemia drugs market and are profiled in MRFR Analysis.

Characterized by the presence of several well-established and small players, the global anemia drugs market appears to be highly competitive and fragmented. International players who are increasingly expanding their footprint in the developing economies, makes it difficult for regional vendors to compete with them, especially in terms of features such as product portfolios, quality, and pricing.  The market is witnessing intensified competition which is expected to get more intensified further during the forecast period. The intense competition prevalent in the market dictates the consolidation among marketers.

Well established players incorporate acquisition, collaboration, partnership, expansion, and product launch in order to gain competitive advantage in this market and to maintain their market position.

In April-2017, Amgen Inc. expanded their commercial collaboration with Novartis for erenumab, which is being investigated for the prevention of migraine. This expanded commercial collaboration was built on a global neuroscience collaboration in Alzheimer's disease and migraine established in 2015 between Novartis and Amgen. This expanded collaboration leveraged Novartis' strong and established presence in neuroscience to more effectively reach people with migraine.

In December-2015, GlaxoSmithKline plc. announced that its global HIV business, ViiV Healthcare, has reached two separate agreements with Bristol-Myers Squibb, to acquire its late-stage HIV R&D assets; and to acquire Bristol-Myers Squibbs portfolio of preclinical and discovery stage HIV research assets.

In October-2016, Elanco U.S., Inc., a subsidiary of Eli Lilly and Company acquired Boehringer Ingelheim Vetmedica, Inc.'s (BIVI) U.S. feline, canine and rabies vaccines portfolio - as well as a fully integrated manufacturing and R&D site - for USD 885 million, including the estimated cost of acquired inventory.

Global Anemia Drugs Market   - Regional Analysis

On the regional backgrounds the Americas leads the global market for anemia drugs owing to huge patient population, increasing healthcare expenditures and presence of the developed economies like U.S. and Canada within the region. Following, the same trends Europe is second in the market. The Asia Pacific region is the fastest growing region due to the developing economies like India and China. Middle East and Africa have the least market share, especially due to the presence of poor economies within the African region. Moreover, stringent government policies within the region are restraining the market growth within the region. On the hand, Middle East leads the regional market due to the presence of developed economies like Kuwait, Qatar, and others within the region and rising healthcare expenses.  

About US:

Market Research Future (MRFR) enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street,5Th Floor, New York,

New York 10013